Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Pharmorubicin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Folacin receptor mediated targeted acetyl pullulan polysaccharide nano granule and preparation thereof
InactiveCN101254309ASmall particle size distribution rangeImprove bioavailabilityPharmaceutical non-active ingredientsAntineoplastic agentsPullulanHydrophobic polymer
The invention discloses a method for preparing folic acid coupled acetyl pullulan polysaccharide and the nanoparticles thereof, a preparation of drug-loaded nanoparticles which take the compound as the carrier and the role of the drug-loaded nanoparticles on the tumor cells. Firstly, the water soluble pullulan polysaccharide is converted to hydrophobic polymers by acetylation, so as to be conductive to the preparation of the nanoparticles and the loading of a hydrophobic drug, and the tumor cells with the high expression of the folate receptor can be targeted after the coupling of the folic acid by esterification. The drug-loaded nanoparticles are prepared by taking epirubicin as a model drug and adopting the solvent dispersion method, and the role of the drug-loaded nanoparticles on the tumor cells are evaluated by the in vitro cell uptake test. The results show that the method for preparing the folic acid-acetyl pullulan polysaccharide nanoparticles by the solvent dispersion method is simple, the reproducibility is good, the expanded production is easy, the drug-loading ratio is high, and the drug-loaded nanoparticles can be taken into the tumor cells by the route of the folate receptor.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Preparation method of porous ferroferric oxide composite nanometre microspheres efficiently loaded with pharmorubicin
InactiveCN104436199AImprove targetingLow toxicityOrganic active ingredientsPowder deliveryActive agentMicrosphere
The invention discloses a preparation method of porous ferroferric oxide composite nanometre microspheres efficiently-loaded with pharmorubicin. The preparation method comprises the following steps: dissolving ferric salts in polyhydric alcohols, adding a surfactant and urea to form a mixed solution, placing the mixed solution in a reaction device and sealing, then reacting at 150-250 DEG C, after that, washing and drying the precipitate, then carrying out amination on porous Fe3O4 microspheres, adding a condensing agent and then carrying out an aminocarboxylic condensation reaction to realize the modification of sodium alginate for the Fe3O4 microspheres, finally loading pharmorubicin by taking the microspheres as carriers. The invention develops a preparation method of a magnetic-targeted medicine carrier which is simple in process, low in cost, high in loading rate, low in toxicity and good in biocompatibility, and the preparation method is of great significance on the popularization of the application of the magnetic-targeted medicine carrier in treatment on breast cancer.
Owner:JINLING INST OF TECH
Anti-tumor combined medicament
InactiveCN102697795AReverse drug resistanceLow toxicityPowder deliveryOrganic active ingredientsEntrapmentQuercetin
The invention discloses applications of pharmorubicin and quercetin to preparation of an anti-tumor combined medicament. The invention further discloses a combined medicament. The pharmorubicin is taken as an anti-tumor medicament; the quercetin is taken as an MDR (Multiple Drug Resistance) reversal agent of the pharmorubicin; PLGA (Poly(Lactic-Co-Glycolic Acid)) is taken as nanoparticle copolymer material; compound nanoparticles of pharmorubicin and quercetin are entrapped during preparation, so that a certain entrapment efficiency and medicament loading amount are achieved; various indexes of the nanoparticles are used for evaluating the property of the medicament; and an in-vitro cell test is used for evaluating the reversed multi-medicament resistance effect of the medicament. EPI-QC (Epichlorohydrin-QC) compound nanoparticles are prepared by adopting an emulsified solvent evaporation method; and according to research on a comparison system, the EPI-QC compound nanoparticles can be used for reverting the medicament tolerance of tumor cells in a certain degree, and the toxicity on normal cells is lowered.
Owner:CHENGDU MEDICAL COLLEGE
Non-spherical drug-loaded particles and controlled release preparation of lactyl polymer and preparation methods thereof
InactiveCN101953776AStable structureNo hemolyticPowder deliveryHydroxy compound active ingredientsSolventSustained-Release Preparations
The invention relates to non-spherical drug-loaded particles and a controlled release preparation of a lactyl polymer and preparation methods thereof. The non-spherical particles of polylactic-co-glycolic acid (PLGA) are prepared by using an emulsion-solvent volatilization method assisted by small molecule materials. The PLGA is used as raw material coated with at least one of the following hydrophobic drugs: all-trans retinoic acid, paclitaxel, epirubicin, camptothecin or roxithromycin, wherein the mass ratio of the hydrophobic drug to a lactyl polymer high polymer material is 1:4-40. The drug-loaded particles of the all-trans retinoic acid are prepared and subjected to in vitro drug release evaluation. The results show that the preparation method has the advantages of simple preparation process, good reproducibility, significantly increased drug loading amount and encapsulation efficiency relative to spherical particles, very good controlled-release effect, no hemolysis initiation and safety use. The novel carrier and preparation have a potential industrial production value in the field of long-circulating controlled release of the hydrophobic drugs.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Antharcycline antitumor antibiotics loaded nano-micelle preparation and preparation method thereof
InactiveCN102973525AAvoid dissociationHigh drug loadingOrganic active ingredientsPowder deliveryPolyesterProtein molecules
The invention discloses an antharcycline antitumor antibiotics loaded nano-micelle preparation, which comprises antharcycline antitumor antibiotics, A-B-C type triblock polymer and assisting agents, wherein the antharcycline antitumor antibiotics is one or more of adriamycin, daunorubicin, pharmorubicin, perarubicin or lacinomycin; and the A-B-C type triblock polymer is polyethylene glycol-polyethylene glycol containing carboxyl on side chain-polyester. According to the preparation, drugs are coated in the nano-micelle by virtue of the coaction of self-assembly of segmented copolymer and electrostatic adsorption, the nano-micelle has uniform and stable grain diameter, the encapsulation efficiency reaches 99 percent, and the prepared nano-micelle preparation is of a spherical structure with grain diameter between 20 and 300nm; and the shell of the micelle is made from polyethylene glycol molecules, so that drugs are prevented from being contacted with enzyme and other protein molecules in blood or identified and swallowed by a reticuloendothelial system in the body, so that the circulating period of micelle in the body can be prolonged.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI +1
Polymer with high-efficient drug loading performance, and preparation method and application thereof
ActiveCN108017783AHigh efficiency loadSolve reunionOrganic active ingredientsPharmaceutical non-active ingredientsPolymer scienceSide chain
Owner:SUZHOU UNIV
Tumor targeted lipidosome drug-delivering system, preparation method and application
InactiveCN106214640AProlong median survivalSignificant effectOrganic active ingredientsMacromolecular non-active ingredientsCyclic peptideTumor target
The invention discloses a tumor targeted lipidosome drug-delivering system, a preparation method and an application. The system comprises a CRNGRGPDC polypeptide modified invisible lipidosome and an antitumor drug, wherein the invisible lipidosome comprises a) hydrogenated soyabean lecithin, b) cholesterol, c) polyethylene glycol-distearoyl phosphatidylethanolamine and d) distearoyl phosphatidylethanolamine-polyethylene glycol-CRNGRGPDC; the mole ratio of the components are as follows: a:b=(5-1):(1-5), a:c=1000:(0.1-100) and a:d=1000:(0.1-100); adriamycin amycin or pharmorubicin is taken as the antitumor drug; the weight percentage of the invisible lipidosome in the system is 75%-98%; the balance is the antitumor drug. The CRNGRGPDC provided by the invention is a cyclic peptide, is taken as aglucon and has pathoklisis with tumor cells. The invention also discloses the preparation method for the polypeptide modified lipidosome containing CRNGRGPDC sequence. The prepared polypeptide modified lipidosome containing CRNGRGPDC sequence is used for intravenous injection and is targeted to the tumor under the tumor EPR effect and CRNGRGPDC mediation. The lipidosome drug-delivering system can be used for targeting and delivering the drugs for tumor diagnosis or treatment.
Owner:EAST CHINA NORMAL UNIV
Sonodynamic liposomal material, preparation method and application thereof in preparing pharmorubicin composite liposomal
InactiveCN102670512APromote absorptionReduce phototoxicityOrganic active ingredientsEnergy modified materialsCholesterolSURFACTANT BLEND
The invention provides a sonodynamic liposomal material, a preparation method and an application thereof in preparing pharmorubicin composite liposomal. The liposomal material comprises 10-40mg of lecithin, 10mg of cholesterol, 5mg of chlorin, 3-5mL of saline citrate buffer solution of which the pH is 4-5 and 0.1-1mL of surfactant. The sonodynamic liposomal material mainly relates to the composite liposomal of pharmorubicin and sonochemical agent chlorin. The preparation method comprises the following steps of: combining the pharmorubicin and the chlorin into the lecithin with a film dispersion method-pH gradient method to form the composite liposomal; and better targeting the pharmorubicin composite liposomal into a tumor tissue to dually kill a tumor cell. The sonodynamic liposomal material is used for treating various tumors and has a good development prospect.
Owner:XI AN JIAOTONG UNIV
Epirubicin liposome as well as preparation method and preserving method thereof
ActiveCN102552146BProperties are not affectedAvoid side effectsOrganic active ingredientsPharmaceutical non-active ingredientsCholesterolActive agent
Owner:JIANGXI HERBFINE HI TECH
Method for treating bladder cancer through promoting pharmorubicin by bacillus calmette guerin vaccine
PendingCN109675023ASmall toxicityImprove treatment efficiencyCompound screeningOrganic active ingredientsSide effectRetention time
The invention discloses a method for treating bladder cancer through promoting pharmorubicin by a bacillus calmette guerin vaccine (BCG), and specifically relates to the field of combined treatment ofthe bladder cancer in clinical medicine. The method comprises a method for researching synergism of the BCG to the pharmorubicin in a cellular level and a method for synergism of the in-vivo BCG to the pharmorubicin. According to the invention, through using the method for researching the synergism of the BCG to the pharmorubicin in the cellular level and the method for the synergism of the in-vivo BCG to the pharmorubicin, a combined medication scheme is provided to improve treatment efficiency and reduce toxic and side effects during drug perfusion. The method disclosed by the invention isnot high in prefused drug concentration, but long in intra-bladder retention time, thereby being better in the anti-tumor effect without generating an adverse reaction.
Owner:GUANGDONG PHARMA UNIV
Polymer nanoparticles for loading alkaline antitumor drugs
InactiveCN102697735ADoes not change local pHGood curative effectPowder deliveryPharmaceutical non-active ingredientsDocetaxel-PNPSide effect
The invention relates to polymer nano-particles for loading alkaline antitumor drugs. A polymer material forming the nanoparticles has biological compatibility and biodegradability, and the polymer material loads the alkaline antitumor drugs; and the polymer material comprises liposome, polylactic acid, polylactic acid-glycolic acid copolymer, polycaprolactone, chitosan, albumin and cyclodextrin; and the alkaline antitumor drug is a micromolecule antitumor drug with pKa being more than 7.4 and comprises adriamycin, pharmorubicin, taxol, docetaxel, vinblastine, vincristine, topotecan and alkaloid Chinese medicine monomers. The polymer nano-particles solve the defects that the pH dependence and physiological drug fastness cannot be reversed. The polymer nano-particles are free from introducing additional drugs, so that the influence on the internal environment of an organism is small, the pH dependence physiological drug fastness is reversed through the polymer nano-particles, not only is the effect realized, but also since no influence is caused for the internal environment of the organism, the polymer nano-particles are safe to use, little in side effect, and wide in application range.
Owner:THE AFFILIATED DRUM TOWER HOSPITAL MEDICAL SCHOOL OF NANJING UNIV
Tumor-targeted multi-purpose nanometer drug delivery system as well as preparation method and applications thereof
The invention discloses a tumor-targeted multi-purpose nanometer drug delivery system as well as a preparation method and applications of the tumor-targeted multi-purpose nanometer drug delivery system. The system comprises multi-purpose nanoparticles modified by tumor penetrating peptide RGERPPR and an anti-tumor medicine, wherein the multi-purpose nanoparticles adopt the T1-T2 dual-mode magnetic resonance contrast agent; the anti-tumor medicine is adriamycin or pharmorubicin; and the weight of the anti-tumor medicine accounts for 10-35 % in the system. The drug delivery system has the following features: the grain diameter is 60-200 nm, and the particles are spherical; the T1 contrast agent Gd-DTPA and the T2 contrast agent Fe3O4 are simultaneously utilized, and the highly accurate diagnosis information is provided; the water solubility and biocompatibility of the medicine are improved, and the curative effects and bioavailability of the medicine are improved; the drug delivery system can be used for intravenous injection, and targets to the tumor tissue by utilizing the RGERPPR mediation effect and the tumor EPR effect, and the system has the obvious inhibiting effect for the growth of the brain glioma tumor; and the drug delivery system can be used for realizing the tumor diagnosis and treatment integration.
Owner:EAST CHINA NORMAL UNIV
Anti-cancer composition loading both platinum compound and synergist
InactiveCN101011351APharmaceutical delivery mechanismPharmaceutical non-active ingredientsCarboplatinMitozolomide
Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.
Owner:JINAN SHUAIHUA PHARMA TECH
Epirubicin liposome as well as preparation method and preserving method thereof
ActiveCN102552146AProperties are not affectedAvoid side effectsOrganic active ingredientsPharmaceutical non-active ingredientsCholesterolActive agent
The invention belongs to the field of pharmaceutical preparation and relates to an epirubicin liposome as well as a preparation method and a preserving method of the epirubicin liposome. The epirubicin liposome is formed by epirubicin and at least one phospholipid as, well as at least one surface active agent or one cryoprotectant or cholesterol which may be contained. The preserving method comprises the following types: preservation at normal temperature, refrigeration preservation, freezing preservation and freezing and drying preservation.
Owner:JIANGXI HERBFINE HI TECH
Preparation of fatty acid-RGD-fatty alcohol conjugate mediated epirubicin targeted liposome and evaluation on anticancer activity
The invention discloses preparation of fatty acid-RGD-fatty alcohol conjugate mediated epirubicin targeted liposome and evaluation on anticancer activity. According to the invention, the conjugate has the following structural formula: CH3(CH2)nCO-Arg-Gly-Asp-OCH2(CH2)10CH3, wherein n is equal to 4-16. An anticancer medicine is introduced into the conjugate to obtain anticancer targeted liposome medicine; the liposome can increase the concentration of the anticancer medicine at a target position, reduce the toxic and side effects of the anticancer medicine at a non-target position, and improve the therapeutic index of the medicine.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Nanometer composite graphene hydrogel system used for breast cancer combined chemotherapy, and preparation method thereof
ActiveCN106237336AEasy to operateMild experimental conditionsOrganic active ingredientsAerosol deliveryDual responseCytotoxicity
The invention discloses a preparation method of a nanometer composite graphene hydrogel system having pH / temperature dual response and simultaneously carrying breast cancer combined chemotherapy drugs comprising paclitaxel and epirubicin. The method comprises the following steps: 1, preparing hydrophobic drug paclitaxel supported graphene PTX@GX; 2, carrying out a free radical polymerization reaction through adopting the PTX@GX as an additive and selecting temperature-sensitive N-isopropylacrylamide NIPAM monomer as first network to prepare single network hydrogel, and carrying out ultraviolet irradiation by selecting pH-responsive acrylic acid AA monomer as a second network in order to synthesize composite graphene double network hydrogel with pH / temperature dual response; 3, loading a hydrophilic drug epirubicin EPI to obtain a PTX and EPI dual supported nanometer composite graphene hydrogel double drug-loading system EPI@PTX@GDL; and 4, detecting the cytotoxicity by using the prepared drug-loading system through an MTM technology, and observing the form of living cells by using a fluorescence microscope. The invention also discloses an application of the prepared composite drug loading system in breast cancer therapy.
Owner:JINLING INST OF TECH
Epirubicin VES (vitamin E succinate) compound and preparation method and application thereof
ActiveCN108434124AHigh activitySmall toxicityPowder deliveryOrganic active ingredientsSide effectTumor therapy
The invention discloses an epirubicin VES compound and a preparation method and application thereof, and relates to a compound of epirubicin (EPI) and vitamin E succinate (VES) having the antitumor activity and a sustained release preparation thereof, wherein the vitamin E succinate can induce apoptosis of tumor cells with high selectivity while causing no toxic and side effect on normal cells. The compound nano particles of the invention can be obtained through a method of co-assembly and nano precipitation, have the property of slowing release of drugs, can efficiently intake tumor cells, and have relatively wide application prospect in the tumor treatment field. In addition, the compound utilizes different antitumor mechanisms of the vitamin E succinate and the epirubicin to play the strong synergistic effect, the administration dosage of the epirubicin can be reduced, and accordingly the toxic and side effects of the epirubicin are lowered.
Owner:XIAMEN UNIV +1
Preparation and application of molecular site-directed targeted and activated short peptide adriamycin
ActiveCN106344930ABroad-spectrum inhibitionReduced chemotherapy toxicityOrganic active ingredientsPharmaceutical non-active ingredientsThreonineTert-leucine
The invention relates to preparation and application of molecular site-directed targeted and activated short peptide adriamycin, in particular to a compound of the following formula I or pharmaceutically acceptable salt of the compound, a medicine composition of the compound and application of the compound in preparation of a medicine for treating or preventing cancers or cancer transferring. In the formula I, X is polar and nonpolar amino acids without charges, such as glycine, alanine, valine, leucine, isoleucine, serine, cysteine, methionine, asparaginate, glutamine and threonine; Z is adriamycin, pharmorubicin or pirarubicin; Z is connected with the lactose-XANL in the formula I through the amino of Z.
Owner:YAFEI (SHANGHAI) BIOLOG MEDICINE SCI & TECH CO LTD
Method, transplant and culture medium for culturing chordoma organoid
The disclosure relates to a method for culturing a chordoma organoid. The method comprises the steps: mixing chordoma tissue cells with a first culture medium and matrix glue, so as to obtain a firstpremix, wherein the first culture medium contains epirubicin, and the epirubicin has a concentration of 15mg / L to 25mg / L by taking the first culture medium as a reference; culturing the first premix for 3 to 7 days, so as to obtain a first culture; acquiring a liquid part from the first culture, and separating cell precipitate from the liquid part, wherein the cell precipitate contains chordoma cells; mixing the cell precipitate with a second culture medium and matrix glue, so as to obtain a second premix, wherein the second culture medium contains the epirubicin, and the epirubicin has a concentration of 5mg / L to 10mg / L by taking the second culture medium as a reference; and subjecting the second premix to culture amplification, thereby obtaining the chordoma organoid.
Owner:北京科途医学科技有限公司
Application of shikonin in preparing medicine for inducing apoptosis
InactiveCN1931152ALow toxicityImprove efficacyOrganic active ingredientsPharmaceutical delivery mechanismMedicineNaphthoquinone
The present invention provides the application of shikonin in preparing medicine for inducing apoptosis. Shikonin has the molecular formula of C16H16O5 and the chemical name of (+)-5, 8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1, 4-naphthoquinone, possesses optical activity, and constitutes one pair of antimers together with isoshikonin. The present invention has clinical application foreground owing to that shikonin can kill several kinds of drug resisting tumor cells in the effect higher than other available clinical medicines and possesses relatively low toxicity.
Owner:ZHEJIANG UNIV
Solid tumor resisting release agent including nimustine and the intensifier
InactiveCN101040843AEasy injectionIncreased sensitivitySolution deliveryPharmaceutical non-active ingredientsTherapeutic effectPolymer
A nimustine slow release injection for treating solid cancer comprises slow release finding and nimustine, or the combination of nimustine and relative booster (pidorubicin, osaliplatinum, adriablastina, amethopterin or the like). The viscidity of slow-release injection is 10-650cp (20-30Deg. C). The anti-cancer effective component can be made into slow release plant agent. The slow release finding substantially comprises macromolecule polymer with biological soluble degradable and absorb property, which can slow release the anti-cancer effective component to cancer part in the degradation process, significantly reduce general reaction and hold effective drug density on cancer. The anti-cancer compound can be arranged part of cancer to reduce the general toxicity reaction, selectively improve the drug density locally, and strengthen the effect of non-surgery treatments as chemotherapy, and radiation therapy or the like. The solid cancer comprises glioma, lung carcinoma, intestinal cancer, breast cancer or the like.
Owner:JINAN KANGQUAN PHARMA TECH
Anti-cancer composition loading both mtrosourea medicament and synergist
InactiveCN101011346APharmaceutical delivery mechanismPharmaceutical non-active ingredientsMitozolomideTreatment effect
Disclosed is a slow release injection agent of anticancer composition containing nitrosourea drugs and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the nitrosourea drugs are selected from Carmustine, Nimustine or Fotemustine, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or temozolomide and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.
Owner:JINAN SHUAIHUA PHARMA TECH
Preparation method of epidoxorubicin lipidosome and application of epidoxorubicin lipidosome in resisting tumors
InactiveCN103550157AProperties are not affectedAvoid side effectsOrganic active ingredientsAntineoplastic agentsCholesterolPhospholipid
The invention belongs to the technical field of medicines, and relates to a preparation method of epidoxorubicin lipidosome and application of the epidoxorubicin lipidosome in resisting tumors. The epidoxorubicin lipidosome is prepared from epidoxorubicin, at least one phospholipid, as well as at least one surfactant, cryoprotectant or cholesterol. Pharmacodynamic tests prove that the epidoxorubicin lipidosome has a remarkable anti-tumor effect, and can be used for treating diseases including but not limited to liver cancer, lung cancer and gastric cancer.
Owner:JIANGXI HERBFINE HI TECH
Preparation method of epirubicin and its intermediate
ActiveCN105229019BHigh purityFew reaction stepsSugar derivativesTert-butyldimethylsilyl chlorideCombinatorial chemistry
The invention provides a method for preparing epirubicin and an intermediate compatible with the method. The preparation method may include: reacting tert-butyldimethylsilyl chloride with N-trifluoroacetyl doxorubicin to obtain compound 1N-trifluoroacetyl-14-O-tert-butyldimethylsilyl doxorubicin Oxidation of compound 1 gives compound 24'-ketone-N-trifluoroacetyl-14-O-tert-butyldimethylsilyl doxorubicin; reduction of compound 2 gives compound 3N-trifluoroacetyl-14-O ‑tert-butyldimethylsilyl epirubicin; and subsequent deprotection and hydrolysis of compound 3 to obtain epirubicin. The method of the invention not only has low cost, few reaction steps, high yield and product purity, but also avoids serious pollution caused by bromination reaction in the traditional method.
Owner:ZHEJIANG HISUN PHARMA CO LTD
Applications of anthracene ring type compounds in preparation of medicines treating AIDS
InactiveCN107041891AObvious anti-HIV effectOrganic active ingredientsAntiviralsT lymphocyteQuantification methods
The invention provides applications of anthracene ring type compounds in preparation of medicines treating AIDS, especially applications of anthracene ring type compounds which are daunorubicin, doxorubicin, pharmorubicin, idarubicin and valrubicin in preparation of medicines treating AIDS. A human T lymphocyte line C8166 and an HIV-1 experimental strain that is HIV-1NL4-3 are selected to perform in-vitro cytotoxicity and anti-HIV activity experiments on the anthracene ring type compounds, wherein the cytotoxicity is detected by using an MTT colorimetric method, and the anti-HIV activity is detected by a symplasm inhibiting test method and an HIV-1p24 antigen quantification method. Through using different dosages of anthracene ring type medicines, results show that the anthracene ring type compounds have obvious anti-HIV effects so that the compounds can be applied for preparing medicines treating AIDS.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Method of avoiding phenomenon of accelerating blood clearance by continuously and repeatedly injecting polyethylene glycol (PEG) lipidosome of epirubicin hydrochloride
InactiveCN103156871AAntibacterial agentsOrganic active ingredientsBlood clearancePolyethylene glycol
The invention belongs to the field of medical technology, relates to a method of avoiding a phenomenon of accelerating blood clearance by continuously and repeatedly injecting polyethylene glycol (PEG) lipidosome of epirubicin hydrochloride, and particularly relates to the influences of the pharmacokinetics behavior of the epirubicin hydrochloride in the second injection of the PEG epirubicin hydrochloride lipidosome by the first injection of blank lipidosome and PEG epirubicin hydrochloride lipidosome and the phenomenon of accelerating blood clearance by continuously and repeatedly injecting the PEG lipidosome. Dosage of PEG epirubicin hydrochloride lipidosome is provided to relieve or avoid the acceleration of the blood clearance on the mentioned basis. By changing the dosage of the epirubicin hydrochloride of the first injection or the continuous injection, the method reaches the purpose of preventing drugs from releasing from the lipidosome and relieving or eliminating the acceleration of the blood clearance.
Owner:SHENYANG PHARMA UNIVERSITY
Recombinant replication-defective adenovirus for expressing hTERT (human telomerase reverse transcriptase) gene and application thereof
The invention provides a recombinant replication-defective adenovirus for expressing an hTERT (human telomerase reverse transcriptase) gene. A target gene hTERT is obtained by virtue of enzyme digestion from a plasmid pIRES2-EGFP(enhanced green fluorescent protein)-hTERT, the target gene hTERT is inserted to downstream of a cytomegalovirus promoter in a pSG218 shuttle vector to obtain a recombinant shuttle vector with the hTERT gene; and the recombinant shuttle vector and a virus framework vector pPE3-F11B are co-transferred to a human embryo kidney 293 cell to obtain replication-defective adenovirus with hTERT. The recombinant adenovirus infects a human multiple myeloma cell, so that the cell excessively expresses the hTERT gene, and therefore, drug resistance of the cell on pharmorubicin is strengthened. The recombinant replication-defective adenovirus disclosed by the invention is mainly used for establishing a multiple myeloma cell strain model for excessively expressing hTERT gene, and further researching a mechanism that the hTERT gene participates in drug resistance of the multiple myeloma cell based on the model.
Owner:ZHEJIANG UNIV
High-activity epirubicin derivative, preparation method thereof and application thereof
ActiveCN102050856ABroad-spectrum antitumor activityHigh activitySugar derivativesHydroxy compound active ingredientsCombinatorial chemistryDrug activity
The invention relates to an epirubicin (EPI) derivative with anticancer activity, in particular to a compound shown as a formula (I) and salts or solvates thereof, a preparation method of the compound shown as the formula (I) and application of the compound serving as medicinal active ingredients. The epirubicin derivative provided by the invention has the equivalent activity and even higher than that of the epirubicin in a cellular level. The formula (I) is shown in the description.
Owner:TIANJIN HEMAY BIO TECH CO LTD +1
2-p-nitrostyryl-4-substituted aminoquinazoline derivatives and their preparation methods and applications
ActiveCN109694358BWeight has no effectHigh yieldOrganic chemistryAntineoplastic agentsOncologyIn vivo
Owner:GUANGXI NORMAL UNIV
A kind of epirubicin ves compound and preparation method and application thereof
ActiveCN108434124BHigh activitySmall toxicityOrganic active ingredientsPowder deliverySide effectTumor therapy
The invention discloses an epirubicin VES compound and a preparation method and application thereof, and relates to a compound of epirubicin (EPI) and vitamin E succinate (VES) having the antitumor activity and a sustained release preparation thereof, wherein the vitamin E succinate can induce apoptosis of tumor cells with high selectivity while causing no toxic and side effect on normal cells. The compound nano particles of the invention can be obtained through a method of co-assembly and nano precipitation, have the property of slowing release of drugs, can efficiently intake tumor cells, and have relatively wide application prospect in the tumor treatment field. In addition, the compound utilizes different antitumor mechanisms of the vitamin E succinate and the epirubicin to play the strong synergistic effect, the administration dosage of the epirubicin can be reduced, and accordingly the toxic and side effects of the epirubicin are lowered.
Owner:XIAMEN UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com